ERBB2 and breast cancer: In addition, the oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2) proteins are crucial biomarkers used to classify BCs into subgroups and subsequently guide adjuvant treatment decisions, including antioestrogen or targeted therapy, in the management of BC [7–9].